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Objectives. The influence of race and age on thrombolytic
therapy, invasive cardiac procedures and outcomes was assessed
in a Veterans Affairs teaching hospital. The influence of Q wave
evolution on the use of invasive cardiac procedures and outcome
was also assessed.
Background. It is not well known how early revascularization
procedures for acute myocardial infarction are delivered or influ-
ence survival in a Veterans Affairs patient population.
Methods. From October 1993 to October 1995, all patients with
myocardial infarction were identified by elevated creatine kinase,
MB fraction (CK-MB) and one of the following: chest pain or
shortness of breath during the preceding 24 h or electrocardio-
graphic (ECG) abnormalities.
Results. Racial groups were similar in terms of age, time to
ECG, peak CK and length of hospital stay. Mortality increased
with age (odds ratio [OR] 1.93, 95% confidence interval [CI] 1.33
to 2.81). A trend toward increased mortality occurred for race
other than Caucasian. Patients meeting ECG criteria were given
thrombolytic agents in 49% of cases, but age, comorbidity count
and Hispanic race decreased the probability of thrombolytic use.
Cardiac catheterization was performed more often after throm-
bolytic agents (OR 1.85, 95% CI 0.97 to 3.54), but less often in
African-Americans (OR 0.59, 95% CI 0.35 to 1.02), older patients
(OR 0.39, 95% CI 0.24 to 0.64) or patients with heart failure (OR
0.30, 95% CI 0.17 to 0.52). Patients evolving non–Q wave infarc-
tions were older and had increased comorbidity counts and trends
toward increased mortality. Angioplasty was chosen less for
patients >265 years old (p 5 0.02); angioplasty and coronary
artery bypass graft surgery were performed less in patients >270
years old (p 5 0.02). Patients treated invasively had lower
mortality rates than those treated medically (p < 0.02).
Conclusions. The use of thrombolytic agents and invasive
treatment plans declined with age, and mortality increased with
age. Trends toward increased mortality occurred with non–Q wave
infarctions and race other than Caucasian.
(J Am Coll Cardiol 1997;29:915–25)
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Acute myocardial infarction is a major cause of death in the
United States. Clinical investigations over the past decade have
been numerous, involving thousands of patients worldwide
(1–3). These trials have provided information that has guided
the prompt use of treatment regimens (4–10). Early revascu-
larization procedures for acute myocardial infarction, such as
administration of thrombolytic therapy or primary angioplasty
(11,12), have significantly reduced mortality in eligible pa-
tients. However, it is not as well known how these interventions
are delivered to varied patient populations in different clinical
settings (13–26). This study examined the influence of race and
age on the use of thrombolytic therapy, invasive cardiac
procedures and subsequent outcomes in a Veterans Affairs
teaching hospital. The influence of Q wave evolution on the
use of invasive cardiac procedures and outcome was also
assessed.
Methods
Patient group. The Houston Veterans Affairs Medical
Center is located in a metropolitan area, is affiliated with
Baylor College of Medicine and relies on housestaff and
subspecialty fellows to provide primary care on the Medical
Service. The hospital has 256 beds staffed by the Medical
Service. The Emergency Department (emergency room and
receiving clinic) is not part of the Medical Service or the
medical school programs. During fiscal year 1994 (October
1993 through September 1994), there were 16,603 discharges
and 322,207 outpatient visits, including 15,939 emergency
room visits and 42,772 receiving clinic (acute care) visits.
During fiscal year 1995 (October 1994 through September
1995), there were 16,873 discharges and 331,216 outpatient
visits, including 14,415 emergency room visits and 46,788
receiving clinic visits. The racial composition of the patients
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discharged during the 2-year period included 62% Caucasian,
32% African-American and 6% Hispanic. The information
reported was gathered as part of the Quality Assessment and
Improvement Program of the Medical Service.
Over a 2-year period (October 1993 through September
1995), charts on all patients admitted to the hospital were
reviewed to determine those with the diagnosis of possible
myocardial infarction. Patients with myocardial infarction were
identified by a higher than normal creatine kinase, MB fraction
(CK-MB) (0 to 12 ng/ml) and .5% of the total CK and one of
the following: chest pain or shortness of breath during the
preceding 24 h or electrocardiographic (ECG) abnormalities.
Study variables. For patients identified as having had a
myocardial infarction, the ECG was reviewed for ST segment
elevation, localization of any change (anterior, inferior, lateral
or nonlocalized) and evolution of Q waves. Patient race, age,
gender, emergency room arrival time (hour and shift [days: 7
AM to 3 PM; evenings: 3 PM to 11 PM; or nights: 11 PM to 7 AM]),
time that initial ECG was obtained, procedures performed
(thrombolytic therapy, cardiac catheterization, coronary angio-
plasty, coronary artery bypass graft surgery [CABG]), peak
CK-MB, length of hospital stay (LOS), discharge medi-
cations (aspirin or ticlid, beta-adrenergic blocking agents or
amiodarone, calcium channel blockers, long-acting nitrates,
angiotensin-converting enzyme [ACE] inhibitors, Coumadin,
lipid-lowering drug) and outcome (survival in the hospital and
follow-up to July 1996) were recorded. If ST segment elevation
was significant enough to warrant evaluation for thrombolytic
therapy, the charts were reviewed to determine if treatment
was given. If treatment was withheld, the reasons for omission
were determined. For those patients treated with thrombolytic
therapy, further information was obtained: admission time
after emergency room arrival, time from entrance to emer-
gency room to initiation of thrombolytic therapy, time from
onset of chest pain to initiation of thrombolytic therapy, type of
thrombolytic agent administered and any complications.
Information on comorbid conditions present during the
hospital period was obtained from the Patient Treatment File,
which is the national data base of information maintained by
the Department of Veterans Affairs on all veteran inpatients.
This data base includes up to nine secondary diagnoses per
hospital admission. Definitions for the following conditions
were created from ICD-9-CM codes for medical diagnoses and
selected procedures: alcohol and illicit drug use, cancer, cere-
brovascular disease (CVD), congestive heart failure, diabetes
mellitus, hemiplegia or paraplegia, hypertension, liver disease,
peripheral vascular disease (PVD), chronic obstructive pulmo-
nary disease (COPD) and renal disease (27,28).
Statistical methods. Data are presented as the mean
value 6 SEM. When indicated, the median is provided.
Comparisons were made by analysis of variance (age, peak CK
and CK-MB, time to obtainment of initial ECG, LOS). Simple
linear regression analysis was used to compare age with
emergency room arrival time, time to obtainment of ECG,
time to treatment with a thrombolytic agent, peak CK or LOS.
Contingency tables were used to determine if the use of
thrombolytic therapy was related to race, age, infarct location,
evolution of Q waves, outcome, emergency room arrival time,
procedures performed or discharge medications. Follow-up
duration was determined by averaging the number of months
from the index admission to July 1996 for each patient. A p
value ,0.05 was considered significant.
Logistic regression was used to examine the relation be-
tween patient characteristics and three dependent variables:
thrombolytic use in patients with significant ST segment ele-
vation (n 5 142), catheterization during the hospital period
and in-hospital mortality. Model construction was performed
using a hierarchic approach; age and race were included in all
models, and individual comorbid conditions were examined if
they were univariately associated (p , 0.2) with thrombolytic
use, catheterization or in-hospital death, or were of strong
clinical interest. In addition, a simple count of the number of
comorbid conditions was also examined in the models. The
comorbidity count was handled as a continuous variable; other
researchers have found that it has predictive power for patient
outcomes (29). However, because the presence of congestive
heart failure alone was strongly associated with the use of
catheterization, it was excluded from the comorbidity count for
the logistic models only and entered separately in each of these
models. Age and comorbidity count were examined both as
continuous variables and as categoric ones with dummy vari-
able coding; when the coefficients in the latter model con-
firmed a linear relation between age or count of comorbid
conditions and the dependent variable of interest, they were
retained as continuous variables (30). In the model predicting
thrombolytic use and catheterization, increasing age had little
effect until it exceeded 70 years; thus, it was handled in these
analyses as a dichotomous variable with that cutoff point. All
results were reported as odds ratios (OR) with 95% confidence
intervals (CI). All logistic regression analyses were performed
using the SAS package.
Results
Incidence of myocardial infarction. Over the 2-year study
period, 1,703 patients were admitted to the Coronary Care
Unit, 685 were evaluated for possible myocardial infarction
and 355 developed myocardial infarctions. Two women were
not included in further analysis. Myocardial infarction oc-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CABG 5 coronary artery bypass graft surgery
CK 5 creatine kinase
COPD 5 chronic obstructive pulmonary disease
CVD 5 cerebrovascular disease
LOS 5 length of hospital stay
PTCA 5 percutaneous transluminal coronary angioplasty
PVD 5 peripheral vascular disease
rt-PA 5 recombinant tissue-type plasminogen activator
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curred in the hospital in 82 patients. There were no differences
among the shifts when patients presented to the emergency
room with respect to the number of patients, time to obtain-
ment of ECG or age. The time of emergency room presenta-
tion was used to visualize the number of patients arriving
during each hour. There was a trend toward a circadian rhythm
with a primary peak incidence in the midmorning and a
secondary peak in the evening (Fig. 1).
Racial groups. There was no difference among the racial
groups in terms of age, time to obtainment of initial ECG,
peak CK or CK-MB, LOS or infarct location (Table 1). The
anterior and inferior infarcts had higher peak CK and CK-MB
levels than the lateral and nonlocalized infarcts (p 5 0.008).
There were no differences among infarct locations in terms of
time to obtainment of initial ECG, LOS, subsequent cardiac
catheterization, percutaneous transluminal coronary angio-
plasty (PTCA) or CABG. For the entire study group, there was
no difference among the racial groups with respect to being
treated with thrombolytic therapy. Aspirin was more fre-
quently prescribed for Caucasians, and this persisted even if
patients taking Coumadin were excluded from the analysis.
There was no difference among the racial groups in the use of
beta-blockers (52.3%), calcium channel blockers (40.8%),
Figure 1. Hourly incidence of myocardial infarction. The time of
emergency room presentation for the study group was used to visualize
the number of patients arriving during each hour. There was evidence
of a circadian rhythm.
Table 1. Characterization of Infarction, Therapy and Outcome Based on Race
Caucasian
(n 5 232)
African-American
(n 5 84)
Hispanic
(n 5 37)
All
(n 5 353)
Age (yr) 63.4 6 0.7 [64] 62.6 6 1.3 [65] 64.7 6 1.6 [67] 63.4 6 0.6 [64]
ECG (min) 36 6 4 38 6 5 35 6 9 36 6 3 [23]
CK (U/liter) 966 6 71 979 6 117 1432 6 302 1017 6 62
CK-MB (ng/ml) 106 6 8 98 6 12 130 6 30 108 6 6
LOS (days) 15.5 6 0.9 15.3 6 1.8 15.8 6 2.3 15.8 6 0.8 [11]
Anterior 67 (29%) 32 (38%) 9 (24%) 108 (30%)
Inferior 80 (34%) 32 (38%) 17 (46%) 129 (37%)
Lateral 37 (16%) 10 (12%) 8 (22%) 55 (16%)
Nonlocalized 48 (21%) 10 (12%) 3 (8%) 61 (17%)
Thx 47 (20.2%) 16 (19%) 7 (20%) 70 (19.8%)
aST 84 (36%) 35 (42%) 23 (62%)† 142 (40.2%)
Non-QMI 162 (70%) 58 (69%) 20 (54%)† 240 (68%)
Catheterization 146 (63%) 43 (51%)† 21 (57%) 210 (59%)
PTCA 54 (23.3%) 14 (17%) 7 (19%) 75 (21%)
CABG 24 (10.3%) 6 (7.1%) 6 (16%) 36 (10.2%)
Aspirin 95%† 88% 85% 92.5%
Beta-blocker 51% 49% 71% 52.3%
Selected comorbidities
Comorbid count 1.38 6 0.08 1.27 6 0.12 1.46 6 0.23 1.36 6 0.07
Cancer 15 (6.5%) 4 (4.8%) 3 (8.6%) 22 (6.3%)
CVD 18 (7.6%) 5 (6.0%) 6 (17.1%) 29 (8.3%)
Heart failure 52 (22.4%) 24 (28.6%)‡ 4 (11.4%) 80 (22.8%)
Hypertension 100 (43.1%) 44 (52.4%) 15 (42.9%) 159 (45.3%)
Diabetes 50 (21.6%) 16 (19.1%) 13 (37.1%)§ 79 (22.5%)
PVOD 18 (7.8%) 3 (3.6%) 4 (11.4%) 25 (7.1%)
COPD 48 (20.7%)* 4 (4.8%) 3 (8.6%) 55 (15.7%)
Renal disease 5 (2.2%) 4 (4.8%) 0 9 (2.6%)
Mortality
In-hospital 24 (10.3%) 12 (14.3%) 8 (21.6%)† 44 (12.5%)
22 months (median) 54 (23.3%) 26 (30.9%) 11 (29.7%) 91 (25.8%)
*p 5 0.001, †p , 0.05, ‡p 5 0.12, §p 5 0.08, compared with other racial groups. Data are presented as mean value 6 SEM with median value in brackets, or as
number (%) of patients. CABG 5 coronary artery bypass graft surgery; CK-MB 5 creatine kinase, MB fraction; COPD 5 chronic obstructive pulmonary disease;
CVD 5 cerebrovascular disease; ECG 5 electrocardiogram; LOS 5 length of hospital stay; PTCA 5 percutaneous transluminal coronary angioplasty; PVOD 5
peripheral vascular obstructive disease; QMI 5 Q wave myocardial infarction; aST 5 ST segment elevation; Thx 5 thrombolytic therapy.
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long-acting nitrates (63.4%), ACE inhibitors (48.4%), Couma-
din (11.8%) or lipid-lowering drugs (20.2%). Patients who did
not survive to discharge were older and had more comorbid
diseases than those who survived (69.6 6 1.1 vs. 62.4 6 0.6
years, p 5 0.0001) (Table 2). There was no difference in total
comorbidity count, but each racial group was unique in terms
of the prevalence of comorbid conditions. There were trends
toward increased mortality for race other than Caucasian,
which may have been related to the particular comorbidity for
Hispanics (diabetes and CVD) and African-Americans (hyper-
tension and heart failure). At a median of 22 months of
follow-up, mortality had doubled overall, with less differences
among the racial groups.
Age groups. If older patients were considered to be those
$65 years old, they differed from their younger cohort in
several ways: mortality was higher; thrombolytics were used
less; lateral or nonlocalized non–Q wave infarctions occurred
more often; catheterization and angioplasty were performed
less often; and the comorbidity count increased (Table 3, Fig.
2). Patients 75 years and older were not hospitalized longer,
nor did they have higher peak CK or CK-MB levels than
younger patients. They did, however, wait longer for the initial
ECG and they were less likely to receive beta-blockers, PTCA
or CABG than younger patients.
Use of thrombolytic therapy. There were 142 patients with
ST segment elevation, meeting the ECG criteria for thrombo-
lytic therapy, and 70 were treated. Reasons cited for choosing
not to administer thrombolytic therapy varied slightly among
racial groups (Table 4). African-Americans had more hyper-
tensive and cerebrovascular exclusions, whereas Hispanics
more often presented in cardiogenic shock or were treated
with primary PTCA. Hispanics were the smallest patient
subgroup, but they were most likely to present with ST
elevation and evolve Q waves (Table 1). Hispanics and older
patients meeting the ECG criteria for thrombolytic therapy
were less often treated (Table 2).
Patients with ST segment elevation who were treated with a
thrombolytic agent were younger and more likely to undergo
cardiac catheterization and to evolve Q waves than those with
ST segment elevation who were not treated (Table 4). Anterior
ST segment elevation and infarction were more common
among African-Americans. There were no differences among
the racial subgroups of patients with ST segment elevation
regarding time to obtainment of initial ECG, peak CK and
CK-MB, LOS, subsequent PTCA or CABG. There were trends
toward decreased mortality for the patients with ST segment
elevation who were treated with thrombolytic agents compared
with those who were not (Caucasian: 2 [4.3%] vs. 4 [10.8%];
African-American: 1 [6.3%] vs. 3 [15.8%]; Hispanic: 2 [29%]
vs. 5 [30%]), except in the small group of Hispanics studied.
The patients with ST segment elevation who died before
discharge were older than those who survived (69.6 6 0.8 years
[n 5 17] and 60.9 6 1.0 years [n 5 125], respectively [p 5
0.03]). Patients treated with thrombolytic agents who died did
not experience delays in initiation of therapy compared with
survivors (presentation to treatment: 93 6 15 min [median 85]
[n 5 5] vs. 120 6 10 min [median 98] [n 5 65]; chest pain to
treatment: 187 6 27 min [median 191] [n 5 5] vs 271 6 21 min
[median 212] [n 5 65], respectively). Mortality after thrombo-
lytic therapy tended to be higher for non–Q wave than for Q
wave infarction (in-hospital: 4.3% vs. 12.5%, p 5 NS; 22
months follow-up: 8.7% vs. 25%, p 5 0.06, respectively), and
these patients who died were older.
There was no correlation between patient age and duration
of chest pain before presentation or time from onset of chest
pain or emergency room arrival to initiation of thrombolytic
therapy. The time from the onset of chest pain or from
presentation to initiation of treatment was not different among
racial groups, infarct locations or with Q wave evolution. There
was a trend toward a progressively longer time from presenta-
tion to treatment with thrombolytic therapy from the day shift
to the night shift (Table 5). There was a significantly longer
time from the onset of chest pain to initiation of treatment
between the day shift and either the evening or night shift. As
part of this time delay, there was a longer time from onset of
chest pain to presentation between the day shift and either the
Table 2. Independent Predictors of Therapy and Outcome
Independent Variable
OR (95% CI)
Thrombolytic Use
(n 5 70)
Catheterization
(n 5 210)
In-Hospital Death
(n 5 44)
Age (10-yr increments) — — 1.93 (1.33–2.81)
Age .70 yr 0.46 (0.20–1.06) 0.39 (0.24–0.64) —
African-American 0.64 (0.28–1.49) 0.59 (0.35–1.02) 1.59 (0.73–3.47)
Hispanic 0.29 (0.10–0.85) 0.76 (0.35–1.67) 2.68 (1.03–7.00)
Comorbidity count* 0.72 (0.49–1.07) 0.88 (0.71–1.10) 1.34 (1.00–1.81)
Heart failure† 0.40 (0.11–1.44) 0.30 (0.17–0.52) 1.66 (0.80–3.41)
Thrombolytic use — 1.85 (0.97–3.54) —
*Number of the following diagnoses assigned to a patient’s hospital discharge: alcohol or drug use, cancer,
cerebrovascular disease, diabetes mellitus, hemiplegia or paraplegia, hypertension, liver disease, peripheral vascular
disease, chronic pulmonary disease, renal disease. †Defined from ICD-9-CM codes as present or absent according to
diagnoses at hospital discharge (27). CI 5 confidence interval; OR 5 odds ratio; n 5 number of events based on entire
population for catheterization and death and based on patients with ST segment elevation for thrombolytic use.
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evening or night shift. For patients treated with thrombolytic
agents, there was no difference between shifts with respect to
the number of patients, race, outcome or age.
The choice of thrombolytic agent included front-loaded
recombinant tissue-type plasminogen activator (rt-PA) (n 5
58), streptokinase (n 5 8) and reteplase (n 5 4). Complica-
tions occurred in five patients (one Caucasian, two African-
Americans and two Hispanic) 57 to 72 years old (mean
[6SEM] 65.6 6 2.7). No patient required transfusion. With
rt-PA one patient each developed epistaxis, gingival bleeding,
hand hematoma and embolic stroke. There was one fatal
intracranial bleed with streptokinase. The two patients with
cerebrovascular events underwent emergent computed tomog-
raphy and had a remote history of stroke (.2 years).
Thrombolytic therapy versus conventional therapy. When
the entire study group was evaluated, the majority of patients
who developed myocardial infarction were not candidates for
thrombolytic therapy (n 5 283). Patients treated with throm-
bolytic therapy (n 5 70) were younger, the initial ECG was
obtained faster and peak CK and CK-MB were higher (p ,
0.001). There were more anterior and inferior Q wave infarcts
in patients treated with thrombolytic agents (p , 0.001).
Cardiac catheterization (p , 0.001) and PTCA (p , 0.05) were
performed more often in patients receiving thrombolytic ther-
apy. The comorbidity count and age .70 years both tended to
decrease the probability of thrombolytic use (Table 2). Patients
treated with thrombolytic agents were more often discharged
on beta-blockers (p , 0.001). In-hospital mortality, when
selected for thrombolytic therapy, tended to be lower than for
conventional therapy (7.1% vs. 13.8%, p 5 0.10), and this
survival benefit persisted long term (14.3% vs. 28.6%, p ,
0.01).
Non–Q wave versus Q wave infarction. The patients with
non–Q wave infarctions were older, had lower peak CK and
CK-MB levels and were less likely to undergo PTCA than
patients with Q wave infarctions, but the use of cardiac
catheterization and CABG was not different (Table 6). The
incidence of non–Q wave infarction was more common among
Caucasians and African-Americans than Hispanics (Table 1).
Evolution of a non–Q wave infarction was more likely in
patients without ST segment elevation or thrombolytic therapy
and included more lateral and nonlocalized infarcts. Patients
with non–Q wave infarctions were more often discharged on
calcium channel blockers and ACE inhibitors, whereas pa-
tients with Q wave infarctions were discharged on beta-
Figure 2. Age distribution. The age (by decade) distribution of all
infarcts and patients treated with thrombolytic agents and the age
distribution of patients presenting with or without ST segment eleva-
tion. Older patients were treated with thrombolytic agents less often
and more often presented without ST segment elevation.
Table 3. Characterization of Infarction, Therapy and Outcome Based
on Age
,65 Years Old
(n 5 178)
$65 Years Old
(n 5 175)
$75 Years Old
(n 5 48)
Age (yr) 54.7 6 0.6 [57] 72.3 6 0.4 [71] 79.4 6 0.6 [78.5]
ECG (min) 36 6 3 [23] 37 6 4 [23] 59 6 14 [27]§
Anterior 63 (35%)* 45 (26%) 14 (29%)
Inferior 68 (38%) 61 (35%) 17 (35%)
Lateral 21 (12%)* 34 (19%) 9 (19%)
Nonlocalized 26 (15%)* 35 (20%) 8 (17%)
Thx 45 (25%)* 25 (14.3%) 4 (8.3%)
aST 75 (42%) 67 (38%) 17 (35%)
Non-QMI 112 (63%)* 128 (73%) 37 (77%)
Catheterization 120 (67%)* 90 (51%) 17 (35%)
PTCA 49 (27.5%)* 26 (14.8%) 5 (10.4%)\
CABG 17 (9.6%) 19 (10.9%) 3 (6.3%)\
Aspirin 93% 92% 93.6%
Beta-blocker 56% 48% 37%\
Selected comorbidities
Comorbid count 1.11 6 0.09* 1.62 6 0.09 1.63 6 0.18
Cancer 4 (2.3%)* 18 (10.3%) 8 (16.7%)§
CVD 15 (8.4%) 14 (8.9%) 2 (4.2%)
Heart failure 28 (15.7%)* 53 (30.3%) 14 (29.2%)
Hypertension 74 (41.6%) 85 (48.6%) 26 (54.2%)
Diabetes 35 (19.7%) 45 (25.7%) 10 (20.8%)
PVOD 6 (3.4%)† 19 (10.9%) 5 (10.4%)
COPD 20 (11.2%)‡ 36 (20.6%) 9 (18.8%)
Renal disease 4 (2.3%) 5 (2.9%) 2 (4.2%)
Mortality
In-hospital 11 (6.2%)* 33 (18.9%) 12 (25%)
22 months (median) 25 (14.0%)* 66 (37.7%) 21 (43.8%)
*p , 0.001 for ,65 years old compared with $65 years old. †p , 0.01 for
,65 years old compared with $65 years old. ‡p , 0.05 for ,65 years old
compared with $65 years old. §p , 0.001 for ,75 years old compared with $75
years old. \p 5 0.02 for $75 years old compared with $75 years old. Data are
presented as mean value 6 SEM with median value in brackets, or as number
(%) of patients. Abbreviations as in Table 1.
919JACC Vol. 29, No. 5 MICKELSON ET AL.
April 1997:915–25 MYOCARDIAL INFARCTION OUTCOME IN A TEACHING HOSPITAL
blockers. The simple comorbidity count, prevalence of prob-
lematic comorbid conditions and mortality tended to be higher
in patients with non–Q wave infarctions.
Invasive versus noninvasive treatment plans. Cardiac cath-
eterization was performed in 210 patients. These patients were
younger and were more often treated with thrombolytic agents
(p , 0.001). However, LOS was longer (p , 0.05). African-
Americans were less likely to undergo cardiac catheterization,
as were older patients (Table 2). Heart failure decreased the
probability of cardiac catheterization. Patients undergoing
cardiac catheterization were more often discharged on aspirin,
beta-blockers and calcium channel blockers (p , 0.001),
whereas patients who did not have catheterization were more
often discharged on ACE inhibitors (p , 0.05). In-hospital
mortality, when selected for cardiac catheterization, was lower
than for noninvasive therapy (4.8% vs. 24.1%, p , 0.001), and
this survival benefit persisted long term (13.8% vs. 43.2%, p ,
0.001).
The subsequent treatment plans—PTCA versus CABG
versus medical therapy—differed in several ways. Patients
undergoing PTCA were younger, more often had ST segment
elevation and developed Q waves (p , 0.01). Coronary angio-
plasty was performed less often in patients $65 years old than
in the younger cohort (Table 3). The three deaths after PTCA
occurred more than 4 days after the procedure in older
patients with previous CABG and severe left ventricular
dysfunction. Bypass graft surgery was not frequently pursued in
the immediate postinfarction period; however, all these pa-
tients survived the initial hospital period despite having the
highest comorbidity count (Table 7). Patients with Q wave
Table 4. ST Segment Elevation Among Racial Groups: Use of Thrombolytic Agents and Invasive Therapy
Caucasian
(n 5 84)
African-American
(n 5 35)
Hispanic
(n 5 23)
All (n 5 142)
Thx
(n 5 70)
No Thx
(n 5 72)
Age (yr) 61.9 6 1.3 60.8 6 1.9 64 6 1.9 59.4 6 1.3† 64.7 6 1.3
Anterior 28 (33%) 20 (57%)* 7 (30%) 27 (39%) 28 (39%)
Inferior 53 (63%) 15 (43%)* 14 (61%) 42 (60%) 40 (56%)
Lateral 3 (4%) 0 2 (9%) 1 (1.4%) 4 (5%)
Non-QMI 33 (39%) 13 (37%) 11 (48%) 24 (34%)† 33 (46%)
Thx 47 (56%) 16 (46%) 7 (30%)
Exclusion Thx
ECG missed 7 (19%) 1 (5%) 2 (12.5%) 10 (14%)
.12 h chest pain 15 (41%) 6 (32%) 6 (38%) 27 (38%)
Cancer 4 (11%) 3 (16%) 1 (6%) 8 (11%)
GI bleed 3 (8%) 1 (5%) 0 4 (5.5%)
Stroke 3 (8%) 4 (21%) 1 (6%) 8 (11%)
Htn (DBP
.120 mm Hg)
0 3 (16%) 0 3 (4%)
Shock 2 (5%) 1 (5%) 2 (12.5%) 5 (7%)
1° PTCA 0 0 2 (12.5%) 2 (3%)
Recent operation 3 (8%) 0 1 (6%) 4 (5.5%)
Other 0 0 1 (6%) 1 (1%)
Catheterization 61 (72%) 22 (63%) 14 (61%) 54 (77%)† 43 (60%)
PTCA 27 (32%) 9 (26%) 7 (30%) 22 (31%) 21 (29%)
CABG 10 (11.9%) 2 (5.7%) 4 (17%) 8 (11.4%) 8 (11.1%)
Mortality
In-hospital 6 (7.1%) 4 (11.4%) 7 (30%) 5 (7.1%)‡ 12 (16.7%)
22 months (median) 14 (16.6%) 8 (23%) 9 (39%) 9 (12.9%)‡ 22 (30.6%)
*p , 0.01 for infarct location among racial groups. †p , 0.05 and ‡p 5 0.07 for thrombolytic therapy (Thx) compared with no thrombolytic therapy. Data are
presented as mean value 6 SEM or as number (%) of patients. DBP 5 diastolic blood pressure; GI 5 gastrointestinal; Htn 5 hypertension; 1° PTCA 5 primary
percutaneous transluminal coronary angioplasty. Other abbreviations as in Table 1.
Table 5. Timeliness of Thrombolytic Therapy During Hospital Shifts
Day
(n 5 22)
Evening
(n 5 27)
Night
(n 5 21)
All
(n 5 70)
Chest pain to presentation 90 6 14* 212 6 38 148 6 25 152 6 18 [120]
ER arrival to ECG 35 6 10 26 6 6 19 6 3 23 6 3 [18]
Presentation to treatment 105 6 15 111 6 12 146 6 20 118 6 9 [98]
Chest pain to treatment 186 6 16* 316 6 38 294 6 24 265 6 20 [204]
*p , 0.05. Data (in minutes) are presented as mean value 6 SEM with median in brackets. ECG 5 electrocardio-
gram; ER 5 emergency room.
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infarctions did not undergo surgical treatment for at least 7
days after admission, accounting for the longer hospital period
with this treatment plan. Both PTCA and CABG were per-
formed less often in patients $75 years old. These patients
selected for invasive treatment plans had lower mortality rates
than those treated medically.
Discussion
Incidence of myocardial infarction. The acute coronary
syndromes (myocardial infarction and unstable angina) are a
major health concern in the United States with regards to
mortality, morbidity and health care delivery. Use of throm-
bolytic therapy and invasive treatment for acute myocardial
infarction in a Veterans Affairs Medical Center affiliated with
a medical school were scrutinized in this study. The potential
study group—patients admitted with the diagnosis of possible
myocardial infarction (2.0%)—and the final study group—
patients with myocardial infarction (1.0%)—represent a small
percentage of the patients discharged from the hospital during
the 2-year period. Patients who were candidates for thrombo-
lytic agents and those who were subsequently treated represent
a fraction of the population. Patients with myocardial infarc-
tion had a high in-hospital mortality rate. Mortality in the
hospital and at a median of 22 months of follow-up was better
in patients selected for thrombolytic therapy or invasive car-
diac procedures (catheterization, PTCA or CABG), or both.
Racial groups. Many of the large studies, when racial
composition is reported, are .90% Caucasian (15,16,31–33).
Our study group is unique when compared with both these
large studies and smaller studies in public hospitals (34).
Despite controlling for age, comorbidity count and heart
failure, Hispanic patients meeting the ECG criteria for throm-
bolytic therapy were less often treated than Caucasians or
African-Americans. However, the two primary angioplasties
performed were in Hispanic men. Overall, our Hispanic pop-
ulation included older men with large infarctions and an
increased incidence of cardiogenic shock, which accounts for
the poor survival in this particular group. Our study evaluated
the use of invasive procedures in a very specific patient group,
those with acute myocardial infarction during the index hospi-
tal period. This group of patients should be more homoge-
neous with respect to treatment among racial groups than
other ischemic syndromes, yet there were significantly fewer
African-Americans who underwent cardiac catheterization.
This persisted despite controlling for trends toward increased
hypertension and heart failure in African-Americans. There
appears to be a well-documented trend toward less invasive
strategies in African-Americans (21–26,31,35), which in our
patients is associated with a trend toward increased mortality.
However, one recent retrospective analysis within the Depart-
ment of Veterans Affairs found that although African-
Americans did not undergo catheterization or revasculariza-
tion procedures as often after a myocardial infarction, their
survival was similar to Caucasians (35). Thus, invasive treat-
Table 6. Patient Profiles Based on Evolution of Q Waves
QMI
(n 5 113)
Non-QMI
(n 5 240)
Age (yr) 61 6 1.1 [62] 65 6 0.7 [65.5]*
ECG (min) 39 6 6 [21] 33 6 3 [24]
Peak CK (U/liter) 1869 6 142 614 6 43†
Peak CK-MB (ng/ml) 196 6 16 65 6 5†
LOS (days) 15.4 6 1.3 [11] 15.5 6 1.0 [11]
Anterior 39 (35%) 69 (29%)‡
Inferior 69 (61%) 60 (25%)‡
Lateral 4 (3.5%) 51 (21%)‡
Nonlocalized 1 (0.9%) 60 (25%)‡
Thx 46 (41%) 24 (10%)†
aST 85 (75%) 57 (24%)†
Catheterization 73 (65%) 137 (57%)
PTCA 35 (31%) 40 (17%)*
CABG 12 (10.6%) 24 (10%)
Aspirin 93.7% 92%
Beta-blocker 62% 48%§
Calcium channel blocker 30% 46%*
ACE inhibitor 42% 51%\
Selected comorbidities
Comorbid count 0.96 6 0.10 1.55 6 0.08‡
Cancer 7 (6.2%) 15 (6.3%)
CVD 9 (8.0%) 20 (8.3%)
Heart failure 12 (10.6%) 69 (28.8%)†
Hypertension 36 (31.9%) 123 (51.3%)‡
Diabetes 20 (17.7%) 60 (25.0%)\
PVOD 7 (6.2%) 18 (7.5%)
COPD 10 (8.9%) 46 (19.2)*
Renal disease 1 (0.9%) 8 (3.3)
Mortality
In-hospital 9 (7.9%) 35 (14.6%)¶
22 months (median) 22 (19.5%) 69 (28.8%)¶
*p , 0.01. †p , 0.0001. ‡p , 0.001. §p , 0.05. \p 5 0.13. ¶p 5 0.08. Data
are presented as mean value 6 SEM with median value in brackets, or as number
(%) of patients. ACE 5 angiotensin-converting enzyme. Other abbreviations as
in Table 1.
Table 7. Patient Profile and Treatment During Index
Hospital Period
CABG
(n 5 36)
PTCA
(n 5 75)
Medical
Treatment
(n 5 242)
Age (yr) 62.8 6 1.6 [65] 59.5 6 1.4 [61]‡ 64.7 6 0.7 [66]
LOS (days) 27 6 3 [23]* 16.6 6 1.3 [13] 13 6 1 [10]
Selected comorbidities
Comorbid count 1.61 6 0.23 0.83 6 0.11‡ 1.49 6 0.08
CVD 5 (13.9%) 1 (1.3%)§ 23 (9.5%)
Heart failure 6 (16.7%) 6 (8.0%)\ 69 (28.5%)
Hypertension 15 (41.7%) 24 (32.0%)‡ 120 (49.6%)
Diabetes 13 (36.1%)† 13 (17.3%) 54 (22.3%)
COPD 8 (22.2%) 8 (10.7%) 40 (16.5%)
Mortality
In-hospital 0% 3 (4%) 41 (16.5%)*
22 months (median) 1 (2.8%) 9 (12%) 81 (33.5%)*
*p , 0.0001. †p 5 0.07. ‡p , 0.01. §p , 0.05. \p , 0.001. Data are presented
as mean value 6 SEM with median value in brackets, or as number (%) of
patients. Abbreviations as in Table 1.
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ment plans may not provide a better outcome or improved
survival for all patients. However, there is little clinical trial
data for racial groups other than Caucasians to guide manage-
ment (31–33,36–40). There was also a difference in medical
therapy among the races; aspirin was prescribed more often for
discharged Caucasians than for the other racial groups. Un-
fortunately, specific data on conditions such as gastrointestinal
bleeding, structural intracranial abnormalities and severe hy-
pertension that may have prevented or hindered the use of
aspirin were not obtained. Our study group was too small to
comment on differences in the use of PTCA or CABG among
the racial groups.
Age groups. As in our group, other investigators (31) have
found that mortality in myocardial infarction increases with
age, whereas the probability of receiving thrombolytic agents
or an invasive treatment plan decreases. However, when
thrombolytic therapy or an invasive treatment plan was chosen,
survival improved, regardless of age. In these older patients,
when thrombolytic agents are contraindicated, a different
approach will be required to improve survival (i.e., perhaps
earlier cardiac catheterization and revascularization proce-
dures).
Use of thrombolytic therapy. In this particular study group,
19.8% of the patients with symptoms within the past 24 h who
developed a myocardial infarction received thrombolytic ther-
apy. This is lower than the 35.1% reported from the National
Registry of Myocardial Infarction (13) but not different from
the Myocardial Infarction Triage and Intervention (MITI)
project (31) (Table 8 was constructed to facilitate comparison
of our data with other studies). Patients with diagnostic ECG
changes (localized ST segment elevation) were treated in 49%
of the cases, similar to the 52% treated in Global Utilization of
Streptokinase and TPA for Occluded Arteries (GUSTO). If a
more standard time window were used (chest pain ,12 h), we
treated 58% of patients with diagnostic ECG changes. By
liberal guidelines, including chest pain duration up to 24 h and
regardless of age, 65.4% of eligible patients without significant
contraindications were treated. The remainder of eligible
patients were not treated because the ECG changes were not
appreciated or the housestaff and cardiology fellow were
unable to obtain, or the patient was unable to provide, a good
history. Most often the patient would describe vague, intermit-
tent chest pain over the preceding several days, despite having
significant ST segment elevation at presentation. During the
study period, there was one fatal bleeding incident—an intra-
cranial bleed after administration of streptokinase (1.4%). It
may be difficult in a teaching hospital with this particular
patient group to increase the percentage of patients safely
treated with thrombolytic agents.
The majority of patients were treated with front-loaded
rt-PA (82.9%). Mortality in the treatment group is within the
range of the various study groups in the GUSTO trial, but it is
probably higher than the 5.9% reported by the National
Registry of Myocardial Infarction or the 4.9% reported by the
Thrombolysis in Myocardial Infarction (TIMI) phase II trial
(1,13,36) (Table 8). These mortality differences are most likely
Table 8. Studies of Acute Myocardial Infarction: Management and Outcome
Yedidia (34)
Public/Private
MITI (31)
HMO/Private
GUSTO (32)
US/Canada
TIMI II (36)
Thx
SAVE (16)
US/Canada
NRMI (13)
Thx/No Thx
Pilot (17)
US/Canada
HVAMC
Thx/No Thx
Thx Rx — 23%/22% All All 34%/31% 35% 33%/26% 19.8%
Age (yr) — 68†/66*† 61†/62† 57 59/59 59/66*\ 69†/65*† 59†/66*†
Race (% white) 18%/78% 93%/92% 91%/91% 88% 86.3%/96.5%* — 83%/93%* 68%/66%
LOS (days) — 8/7.3 — — — 7.5†/7.5† 7†/9*† 10†/11†
CP to Rx — — 160†/171*† 156 — 165† — 204†
ER to Rx — — — — — 57† — 98†
Cath. 25%/73%* 41%/60%* 72%/25%* — 78%/48%* 71%/48%* 55%/34%* 77%/56%*
PTCA 3%/16% 6%/26%* 29%/11%* — 27%/11%* 30%/16%* 30%/13%* 31%/19%*
CABG 6%/14% 11%/11% 14%/3%* 11.1% 22%/13%* 13%/11%* 10%/4%* 11%/10%
Htn 47%/43% — 41%/31%* 36% 46%/35%* — 50%/49% 30%/49%*
Diabetes — — 15%/12% 12.4% 24%/18%* — 21%/33%* 13%/25%*
CHF — 11%/12% — 2.2% — — — 6%/27%*
Aspirin — — — 13%§ 58%/63%* 84%/62%* 83%/93%* 93%/93%
Beta-blocker — — 47–71%‡ 14.4%§ 28%/23%* 36%/30%* — 70%/48%*
ACE — — 13–18%‡ — — — — 40%/50%
Ca blocker — — 24–34%‡ 8.7%§ 32%/27%* 30%/42%* — 31%/43%
Mortality — 7.8%/9.3% 6.8%/7.6%* 4.9% 11%/11% 5.9%/13.1%* 12%/11% 7.1%/13.8%
Follow-up — In-hospital 30 days 42 days 1 yr In-hospital In-hospital In-hospital
*Significant difference between study groups. †Median value. ‡GUSTO ref. 14. §TIMI ref. 33. \Only men. ACE 5 angiotensin-converting enzyme inhibitor;
Cath. 5 cardiac catheterization; Ca blocker 5 calcium channel blocker; CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart failure; CP to Rx
(min) 5 time from onset of chest pain to initiation of thrombolytic therapy; ER to Rx (min) 5 time from hospital presentation to initiation of thrombolytic therapy;
GUSTO 5 Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial; HMO 5 health maintenance organization;
Htn 5 hypertension; HVAMC 5 Houston Veterans Affairs Medical Center; LOS 5 length of hospital stay; MITI 5 Myocardial Infarction Triage and Intervention
Project; NRMI 5 National Registry of Myocardial Infarction; PTCA 5 percutaneous transluminal coronary angioplasty; Thx Rx 5 thrombolytic therapy; SAVE 5
Survival and Ventricular Enlargement Study; TIMI II 5 Thrombolysis in Myocardial Infarction Phase II trial.
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related to our small sample size, the 24-h time window for
treatment and the increased number of older non-Caucasian
patients. In a racial subgroup analysis of the TIMI II data, the
African-American and Hispanic men were more than a decade
younger than our patients, and inclusion criteria required
presentation within 4 h of chest pain onset (41). We did not
find a difference in time to initiation of therapy and the
outcome among patients who received thrombolytic therapy,
but our time to initiation of therapy after the onset of chest
pain was probably longer than that in reported studies. Any
delay in treatment is to be avoided, because it is well recog-
nized that the earlier treatment can be initiated, the lower the
mortality (42–45).
Recent studies to define delays in initiating treatment
included time spent obtaining an ECG by personnel not
present in the emergency department, bedside cardiology
consultation and preparation of the infusion in an off-site
pharmacy (46–48). In our study, electrocardiography was
performed by a technician who had to be paged to the
emergency department, and all patients were evaluated by the
cardiology fellow before treatment. Patients presenting during
the evening and night shifts took more time getting to the
hospital, and there was a progressively longer time from
presentation to treatment. Nighttime delays in the administra-
tion of thrombolytic therapy were also reported in the National
Registry of Myocardial Infarction (10). Although the number
of veterans presenting with acute myocardial infarction was
similar during each shift of the day, there was a trend toward
a circadian rhythm at presentation (49,50).
Non–Q wave versus Q wave infarction. Evolution of
non–Q wave infarction after thrombolytic therapy occurred in
over one-third of our patients, slightly higher than has been
reported in other studies (33,51). The mortality rate for non–Q
wave infarction after thrombolytic therapy was low and tended
to be lower than that for Q wave infarctions at 1 (33) or 2 years
(51) in these studies. In our small study group, mortality after
thrombolytic therapy tended to be higher for non–Q wave
infarctions, but these patients were also older. The majority of
non–Q wave infarctions in our study occurred in patients who
did not have ST segment elevation or receive thrombolytic
therapy. Recent information suggesting elderly patients with
non–Q wave infarctions have a lower in-hospital mortality rate
than those with Q wave infarctions was not confirmed in our
study group (52). Also, in our study group, non–Q wave
infarctions were predominant and these patients were older
and had more comorbid diseases than patients with Q wave
infarctions. Mortality, both in the hospital and at 22 months of
follow-up, in patients with non–Q wave infarctions was high
and remained nearly twice that of patients with Q wave
infarctions.
Invasive treatment plans. Many of the patient characteris-
tics reported in the National Registry of Myocardial Infarction
are comparable to our study patients (Table 8). Patients
treated with thrombolytic agents were younger, had localizing
ECG changes and showed improved survival. As with our
patients, invasive procedures were performed more often in
patients receiving thrombolytic therapy (10). These rates for
procedures after thrombolytic therapy are similar to the
GUSTO-1 substudy (14) or the Fee-for-Service hospitals in the
MITI project (31). Our use of angiography and revasculariza-
tion procedures early after myocardial infarction was similar to
that in U.S. hospitals in several reports (16,17). In the popu-
lation $65 years old with acute myocardial infarction, our use
of angiography and revascularization procedures was similar to
that in the Medicare population reported for Texas (15).
Coronary angioplasty was performed less often in patients 65
years or older. Bypass graft surgery was performed less often in
patients 70 years or older. Patients over 65 years old had higher
comorbidity counts, which may have contributed to a selection
bias away from invasive treatment plans. Patients selected for
cardiac catheterization, which requires a cardiologist in the
patient’s care, were discharged on a more aggressive antiangi-
nal regimen than patients who did not undergo cardiac cath-
eterization. However, the prevalence of heart failure was
higher in patients who did not have catheterization, a reason-
able explanation for using ACE inhibitors rather than calcium
channel blockers and possibly beta-blockers. Both groups used
more (13,16,17,53) or the same amount (14) of aspirin and
beta-blocker reported previously. Within the Veterans Affairs
Medical Centers, there are no direct financial incentives or
insurance issues affecting the use of procedures or medica-
tions.
Hospital stay was 3 days longer in patients undergoing
cardiac catheterization. This was in part due to delays in
deciding the patients’ need to have cardiac catheterization
performed, based on either information obtained from the
echocardiogram, stress test or clinical scenario. To train house-
staff and fellows in both the thought processes and techniques,
a more liberal use of time and testing may be undertaken in a
serial rather than a parallel fashion. Unless the procedure is
urgent or emergent it will be carried out during routine hours
of a 5-day week. The decision to have personnel available in
the cardiac noninvasive laboratory, nuclear medicine labora-
tory or cardiac catheterization laboratory at all times to
perform studies reflects local administrative and economic
strategies (18,19,32,54).
Study limitations. This was not a randomized trial of
invasive strategies. We cannot conclude that improved survival
among patients treated with thrombolytic agents or revascu-
larization, or both, was due to the treatment itself. We do not
know whether patients were chosen for less invasive medical
therapy based on 1) sound medical judgment, which deter-
mined a poor outcome to be inevitable; 2) the patients’
preferences for the noninvasive regimen; or 3) the physicians’
preferences regarding the provision of invasive therapies.
Those patients who did not survive to hospital discharge were
older and had more heart failure than those treated with
thrombolytic agents or those undergoing cardiac catheteriza-
tion. There were no data collected on in-hospital medications,
which may have had an impact on survival.
Given the small number of patients treated, the data
available might not be sufficient to conclude that thrombolytic
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treatment unequivocally improves outcomes for each racial or
age group. In particular, Hispanics tended to have more
problematic comorbid diseases (i.e., CVD and diabetes).
Among Hispanics meeting ECG criteria for thrombolytic
therapy, there was no survival benefit to treatment. Bypass
grafting was chosen for a significant percentage of Hispanics,
which reflects recent practices in the choice of revasculariza-
tion procedure for diabetics. In contrast, those African-
Americans with ST segment elevation who were given throm-
bolytic agents had a low mortality. The data base on comorbid
diseases may be incomplete and thus not accurately display a
potential explanation for increased mortality within a racial
group. The few patients over 75 years old who were treated
with thrombolytic agents did very well, but studies with large
numbers of elderly patients have determined that mortality in
this age group is still very high (1).
There appears to be a relatively large percentage of older
patients with non–Q wave infarctions who had several comor-
bid diseases and an associated high mortality. Chart review
yielded vague or no data regarding duration of symptoms
before presentation, unless thrombolytic agents were adminis-
tered. Some of these older patients with non–Q wave infarc-
tions may have presented to the hospital later with serious
complications (i.e., heart failure), which hindered any treat-
ment plan that might have improved survival.
We limited our analysis to revascularization during the
index hospital period for acute myocardial infarction. Some
patients undoubtedly underwent cardiac catheterization and
revascularization during a subsequent admission. However, it
is unlikely that the lower rate of catheterizations among
African-Americans would be completely offset by an excess of
these procedures in the months after discharge. Moreover,
some patients, particularly those with Medicare, may have
obtained services outside of the Veterans Affairs Medical
Center, making complete ascertainment of invasive procedures
among our patients difficult. Similarly, our outcome informa-
tion may be incomplete if patients died outside of a Veterans
Affairs Medical Center and we were not notified of the event.
Conclusions. We have shown that a busy teaching hospital
in a large metropolitan center can safely provide invasive
cardiac services at rates comparable to institutions that partic-
ipated in major investigations and randomized trials. Two-year
follow-up in our patient group shows a very high mortality rate
despite medical regimens that are as good as those published
in large clinical trials. Our study group included elderly and
more ethnically diverse patients than can be found in most
major published reports. Efforts to improve our care of
patients with acute myocardial infarction could include 1)
aggressively educating emergency staff, housestaff and cardiol-
ogy fellows in ECG interpretation and chest pain history taking
so that more eligible patients will be offered thrombolytic
therapy or primary angioplasty; 2) improving the time to
thrombolytic treatment by developing a “thrombolytic team”;
3) vigilance regarding treatment of changing risk factors and
disease progression; and 4) continued patient education of the
population at risk regarding the need to present to the hospital
as quickly as possible after the onset of symptoms. This last
task may be difficult to achieve because over one-fourth of the
study group resides in Texas counties other than that of the
Houston Veterans Affairs Medical Center, making transporta-
tion time an issue. Nevertheless, hospitals determined to
improve the cardiac care they provide would do well to begin
with an examination of their patients with acute myocardial
infarction, as we have done. It is possible that other hospitals
have patients and providers with unique characteristics that
may or may not be comparable to the major published studies
of acute myocardial infarction management available to date.
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